Casdin Capital
Latest statistics and disclosures from Casdin Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are RVMD, BLFS, SRPT, RLAY, ILMN, and represent 52.11% of Casdin Capital's stock portfolio.
- Added to shares of these 9 stocks: RVMD (+$112M), ILMN (+$40M), BLFS (+$15M), Neurogene (+$10M), NTLA (+$8.3M), CDXS (+$5.2M), RLAY (+$5.1M), SNDX, VERV.
- Started 2 new stock positions in SNDX, Neurogene.
- Reduced shares in these 10 stocks: Eqrx (-$88M), MRTX (-$22M), MXCT (-$5.9M), GPCR (-$5.8M), ALNY, BPMC, TSVT, EXAS, SANA, TNGX.
- Sold out of its positions in Eqrx, MXCT, MRTX, SANA.
- Casdin Capital was a net buyer of stock by $57M.
- Casdin Capital has $1.0B in assets under management (AUM), dropping by 12.75%.
- Central Index Key (CIK): 0001534261
Tip: Access up to 7 years of quarterly data
Positions held by Casdin Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv Download as ExcelPortfolio Holdings for Casdin Capital
Casdin Capital holds 36 positions in its portfolio as reported in the December 2023 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
---|---|---|---|---|---|---|
Revolution Medicines (RVMD) | 16.1 | $164M | +215% | 5.7M | 28.68 |
|
Biolife Solutions Com New (BLFS) | 13.9 | $142M | +11% | 8.7M | 16.25 |
|
Sarepta Therapeutics (SRPT) | 9.5 | $97M | 1.0M | 96.43 |
|
|
Relay Therapeutics (RLAY) | 8.0 | $81M | +6% | 7.4M | 11.01 |
|
Illumina Call Option (ILMN) | 4.6 | $47M | +576% | 338k | 139.24 |
|
Structure Therapeutics Sponsored Ads Call Option (GPCR) | 4.5 | $46M | -11% | 1.1M | 40.76 |
|
Intellia Therapeutics (NTLA) | 4.3 | $44M | +23% | 1.5M | 30.49 |
|
Verve Therapeutics (VERV) | 4.1 | $42M | 3.0M | 13.94 |
|
|
Alnylam Pharmaceuticals (ALNY) | 3.7 | $37M | -11% | 195k | 191.41 |
|
Somalogic Class A Com | 3.1 | $32M | 13M | 2.53 |
|
|
EXACT Sciences Corporation (EXAS) | 3.1 | $31M | -8% | 420k | 73.98 |
|
Blueprint Medicines (BPMC) | 3.0 | $30M | -12% | 326k | 92.24 |
|
Pliant Therapeutics (PLRX) | 2.8 | $29M | 1.6M | 18.11 |
|
|
Denali Therapeutics (DNLI) | 2.7 | $28M | 1.3M | 21.46 |
|
|
4d Molecular Therapeutics In (FDMT) | 2.1 | $21M | 1.0M | 20.26 |
|
|
Tenaya Therapeutics (TNYA) | 2.0 | $21M | 6.4M | 3.24 |
|
|
Beam Therapeutics (BEAM) | 1.4 | $14M | -7% | 528k | 27.22 |
|
Abcellera Biologics (ABCL) | 1.3 | $14M | 2.4M | 5.71 |
|
|
Tango Therapeutics (TNGX) | 1.2 | $12M | -9% | 1.2M | 9.90 |
|
Century Therapeutics (IPSC) | 1.0 | $11M | 3.2M | 3.32 |
|
|
Avidity Biosciences Ord (RNA) | 1.0 | $11M | -5% | 1.2M | 9.05 |
|
Neurogene | 1.0 | $10M | NEW | 525k | 19.38 |
|
Pacific Biosciences of California (PACB) | 1.0 | $10M | 1.0M | 9.81 |
|
|
Genedx Holdings Corp Com Cl A (WGS) | 0.8 | $8.5M | 3.1M | 2.75 |
|
|
Fate Therapeutics (FATE) | 0.8 | $7.7M | 2.1M | 3.74 |
|
|
Codexis (CDXS) | 0.6 | $6.1M | +566% | 2.0M | 3.05 |
|
2seventy Bio Common Stock (TSVT) | 0.5 | $5.0M | -41% | 1.2M | 4.27 |
|
Absci Corp (ABSI) | 0.4 | $4.1M | 973k | 4.20 |
|
|
Prime Medicine (PRME) | 0.3 | $3.3M | 367k | 8.86 |
|
|
Syndax Pharmaceuticals (SNDX) | 0.3 | $3.2M | NEW | 150k | 21.61 |
|
Monte Rosa Therapeutics (GLUE) | 0.3 | $2.9M | 511k | 5.65 |
|
|
D Fluidigm Corp Del (LAB) | 0.3 | $2.7M | 1.2M | 2.21 |
|
|
Exscientia Ads (EXAI) | 0.1 | $1.4M | 214k | 6.41 |
|
|
Lianbio Sponsored Ads (LIAN) | 0.1 | $923k | 206k | 4.47 |
|
|
Singular Genomics Systems In (OMIC) | 0.1 | $609k | 1.3M | 0.46 |
|
|
Kronos Bio (KRON) | 0.0 | $155k | 124k | 1.25 |
|
Past Filings by Casdin Capital
SEC 13F filings are viewable for Casdin Capital going back to 2015
- Casdin Capital 2023 Q4 filed Feb. 14, 2024
- Casdin Capital 2023 Q3 filed Nov. 14, 2023
- Casdin Capital 2023 Q2 filed Aug. 14, 2023
- Casdin Capital 2023 Q1 filed May 15, 2023
- Casdin Capital 2022 Q4 filed Feb. 14, 2023
- Casdin Capital 2022 Q3 filed Nov. 14, 2022
- Casdin Capital 2022 Q2 filed Aug. 15, 2022
- Casdin Capital 2022 Q1 filed May 16, 2022
- Casdin Capital 2021 Q4 filed Feb. 14, 2022
- Casdin Capital 2021 Q3 filed Nov. 15, 2021
- Casdin Capital 2021 Q2 filed Aug. 16, 2021
- Casdin Capital 2021 Q1 filed May 17, 2021
- Casdin Capital 2020 Q4 filed Feb. 16, 2021
- Casdin Capital 2020 Q3 filed Nov. 16, 2020
- Casdin Capital 2020 Q2 filed Aug. 14, 2020
- Casdin Capital 2020 Q1 filed May 15, 2020